Screener
MBX Biosciences, Inc. MBX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(23,517) | $(23,880) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,484 | 1,839 |
| Non cash operating lease expense | 34 | 29 |
| Accretion and amortization of marketable securities, net | (579) | (1,343) |
| Depreciation expense | 64 | 77 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s stock-based comp?
- MBX Biosciences, Inc. (MBX) reported stock-based comp of $5.48M in Q1 2026.
- How has MBX Biosciences, Inc.'s stock-based comp changed year-over-year?
- MBX Biosciences, Inc.'s stock-based comp increased by 198.2% year-over-year, from $1.84M to $5.48M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about MBX Biosciences, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude